INmune Bio: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
INmune Bio (NASDAQ:INMB) reported Q4 earnings with an EPS of $-0.47, missing estimates by -7%, and a revenue decrease of $69 thousand from the previous year. The company's past earnings miss was followed by a 4% share price drop.
March 28, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
INmune Bio reported a Q4 EPS of $-0.47, missing estimates by -7%, with a revenue decrease of $69 thousand from the previous year. Previous earnings miss resulted in a 4% stock price drop.
INmune Bio's Q4 earnings miss and the historical context of a stock price drop following previous earnings misses suggest a likely negative short-term impact on INMB's stock price. The revenue decrease further supports this outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100